Register Login

Abiopharma

  • Home
  • About
  • Newsroom
    • News
    • Company List
  • Events
  • Automated Tools
  • Contact

News list

9 Meters Biopharma, Inc. (NMTRQ)

  • Business News
  • Jan. 06, 2026, 19:43 UTC
  • 5
  • 1 comments

How Does the Samsung Galaxy S20 Ultra Hold Up in 2026?

Market reaction Comment Full text

9 Meters Biopharma, Inc. (NMTRQ)

  • Business News
  • Jan. 06, 2026, 19:41 UTC
  • 5
  • 1 comments

Death in Paradise Season 15: Complete Guide (Release Date, Cast, Plot & Updates)

Market reaction Comment Full text

McKesson Corporation (MCK)

  • SEC News
  • Jan. 06, 2026, 19:26 UTC
  • 6
  • 1 comments

Rodgers Thomas L 🔴 sold 276 shares of MCKESSON CORP (MCK) at $816.18 Transaction Date: Jan 05, 2026 | Filing ID: 000002

Comment Full text

Cardio Diagnostics Holdings Inc (CDIO)

  • SEC News
  • Jan. 06, 2026, 19:20 UTC
  • 6
  • 1 comments

Director Fung Peter K 🟢 acquired 2.3K shares (1 derivative) of Cardio Diagnostics Holdings, Inc. (CDIO) at $2.71 Transaction Date: Dec 31, 2025 | Filing ID: 000001

Comment Full text

Cardio Diagnostics Holdings Inc (CDIO)

  • SEC News
  • Jan. 06, 2026, 19:17 UTC
  • 6
  • 1 comments

Director Betts Wendy J 🟢 acquired 2.3K shares (1 derivative) of Cardio Diagnostics Holdings, Inc. (CDIO) at $2.71 Transaction Date: Dec 31, 2025 | Filing ID: 000001

Comment Full text

Cardio Diagnostics Holdings Inc (CDIO)

  • SEC News
  • Jan. 06, 2026, 19:13 UTC
  • 6
  • 1 comments

Director Intrater James 🟢 acquired 2.3K shares (1 derivative) of Cardio Diagnostics Holdings, Inc. (CDIO) at $2.71 Transaction Date: Dec 31, 2025 | Filing ID: 000001

Comment Full text

Cardio Diagnostics Holdings Inc (CDIO)

  • SEC News
  • Jan. 06, 2026, 19:10 UTC
  • 6
  • 1 comments

Director Burton Paul Frederick 🟢 acquired 2.3K shares (1 derivative) of Cardio Diagnostics Holdings, Inc. (CDIO) at $2.71 Transaction Date: Dec 31, 2025 | Filing ID: 000001

Comment Full text

Processa Pharmaceuticals Inc. (PCSA)

  • Technical Exchange News
  • Jan. 06, 2026, 19:03 UTC
  • 18
  • 0 comments

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Comment Full text

Moleculin Biotech Inc. (MBRX)

  • Technical Exchange News
  • Jan. 06, 2026, 19:03 UTC
  • 19
  • 0 comments

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Comment Full text

Estrella Immunopharma Inc. (ESLA)

  • Business News
  • Jan. 06, 2026, 19:02 UTC
  • 8
  • 1 comments

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

Market reaction Comment Full text

9 Meters Biopharma, Inc. (NMTRQ)

  • Business News
  • Jan. 06, 2026, 19:01 UTC
  • 9
  • 1 comments

Xreal Air 2 Pro: Latest Info and Updates

Market reaction Comment Full text

Estrella Immunopharma Inc. (ESLA)

  • SEC News
  • Jan. 06, 2026, 18:56 UTC
  • 4
  • 0 comments

New Form 424B5 - Estrella Immunopharma, Inc. Filed: 2026-01-06 AccNo: 0001213900-26-001686 Size: 356 KB

Comment Full text

9 Meters Biopharma, Inc. (NMTRQ)

  • Business News
  • Jan. 06, 2026, 18:56 UTC
  • 7
  • 1 comments

Why Is Fortnite Not Working? Troubleshooting Steps To Try

Market reaction Comment Full text

Profound Medical Corp (PROF)

  • SEC News
  • Jan. 06, 2026, 18:39 UTC
  • 4
  • 1 comments

(85% Positive) PROFOUND MEDICAL CORP. (PROF) Provides Update on advancement for prostate care

Comment Full text

Zymeworks Inc (ZYME)

  • Business News
  • Jan. 06, 2026, 18:34 UTC
  • 9
  • 1 comments

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Market reaction Comment Full text
  • Previous
  • 593
  • 594
  • 595
  • 596
  • 597
  • Next

Search

News categories

  • Technical Exchange News(10945)
  • Event(2382)
  • SEC News(191988)
  • FDA Approval(10304)
  • Company Report(721)
  • Business News(125319)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin